Startups
RxCelerate is an out-sourced drug development company, delivering complete preclinical drug development programmes and project management for virtual and semi-virtual companies. Our services include routine animal models of human diseases, toxicology and ADME studies. We offer innovative experimental designs (combining efficacy, toxicology and pharmacokinetic end-points in one study or using multivariate statistical frameworks to examine multiple end-points in a single study design) coupled with more than 20 years experience of drug discovery and development. RxCelerate delivers cutting-edge development capability at the same time as cutting costs and timelines to client companies large and small.
Overview
Location
United States, Massachusetts, Cambridge
Employees
11-50
Founded date
2012
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Apr 24, 2025 | Speakers announced for the BioResource Scientific Conference 2025 | We are excited to present our speakers for the 3rd annual NIHR BioResource Scientific Conference, taking place online on Wednesday 25 June 2025 from 9.30am to 12.30pm. Our conference will present a variety of cutting-edge academic and indus... |
| Mar 12, 2025 | Shift Bioscience announces key appointments to advance rejuvenation therapeutics pipeline | Jill Reckless (CEO, RxCelerate) appointed as Translation Advisor Laurence Reid joins as Non-Executive Director, previously Decibel Therapeutics, Warp Drive Bio, Alnylam, and Millennium Pharmaceuticals Cambridge, UK, 12 March 2025: Shift Bio... |
| Feb 18, 2021 | RxCelerate launches Galaxy™: a next-generation antibody discovery platform | RxCelerate launches Galaxy™: a next-generation antibody discovery platform 18-02-2021 RxCelerate, a leading international out-sourced drug discovery and development platform, today revealed details of a new antibody discovery platform, Gala... |
| Jan 27, 2020 | BioMed Realty’s flagship research development at Babraham Research Campus now at 75% pre-let | BioMed Realty’s flagship research development at Babraham Research Campus now at 75% pre-let 27-01-2020 BioMed Realty, a Blackstone portfolio company and a leading provider of real estate solutions to the life sciences community, and RxCele... |
| Apr 30, 2018 | Two biotechs hunt $175 million in Nasdaq pursuit; Keryx CEO Gregory Madison abruptly resigns; RxCelerate buys bioanalytical CRO | → Less than four months after reaping $47 million in Series C financing, Scholar Rock is out for a $75 million IPO. The Cambridge, MA-based company will be focused on preparing its lead program for spinal muscular atrophy,... |
| May 4, 2017 | Z Factor announces £7 million Series A funding to bring lung treatment to clinic | Z Factor Limited announced that it has completed a £7 million Series A investment led by existing investor Medicxi. Cambridge Enterprise & Cambridge Innovation Capital have also joined in the founding round. Add This Share Buttons Found... |
| May 4, 2017 | Z Factor announces £7 million Series A funding to bring lung treatment to clinic | Z Factor announces £7 million Series A funding to bring lung treatment to clinic 04-05-2017 Z Factor Limited announced that it has completed a £7 million Series A investment led by existing investor Medicxi. Cambridge Enterprise & Cambr... |
Reviews 0
FAQ about RXCELERATE LIMITED
When was RXCELERATE LIMITED founded?
RXCELERATE LIMITED was founded in 2012.
What has the press written about RXCELERATE LIMITED?
Parsers VC has collected 8 articles mentioning RXCELERATE LIMITED, among them “Speakers announced for the BioResource Scientific Conference 2025” (Apr 24, 2025) and “Shift Bioscience announces key appointments to advance rejuvenation therapeutics pipeline” (Mar 12, 2025).
Is RXCELERATE LIMITED still active?
Yes, RXCELERATE LIMITED is active; its latest activity on Parsers VC dates from Nov 19, 2025.